GGrantIndex
← Search

BAA-APPLICATION OF HLA DATA TO DEVELOP &IMPROVE VACCINE

$323,711N01FY2000AINIH

Massachusetts Institute Of Technology, Cambridge MA

Investigators

Linked publications & trials

Abstract

Effective immune responses require the development of T lymphocytes specific for antigens presented by self major histocompatibility complex (MHC) class I and class II molecules. Many basic and clinical studies require the detection and enumeration of antigen- specific T lymphocytes, but until recently their detection was inaccurate and cumbersome, requiring extensive tissue culture procedures. New reagents have been developed, comprised of four identical MHC molecules, each presenting a defined antigenic peptide. The reagent is fluorescently labeled to enable the direct detection of T cells that bind the reagent by their specific antigen receptor molecules. Previous research has established the approach for class I MHC molecules that bind to cytotoxic T cells, but reagents based upon class II MHC molecules, which would detect helper T lymphocytes, are less well-developed. This contract will focus on the development and utilization of class II MHC-peptide tetramers to detect and study antigen specific T cells. Studies will include: a) testing various forms of class II MHC-peptide complexes to optimize the reagents, b) demonstrate the reagents~ ability to detect human T cells in clinical samples and c) combine detection with functional T cell assays to increase the information obtained. Because helper T cells are central to virtually all immune responses, this technology is applicable to studies in many areas, including basic immune mechanisms, infectious diseases, vaccination, autoimmunity, transplant rejection, and tumor therapy.

View original record on NIH RePORTER →